1. Scrip
  2. >>Therapy Areas
  3. >>Respiratory

Dupixent FDA Asthma Review Bolsters Sanofi And Regeneron

 
• By Kevin Grogan

Already approved for atopic dermatitis, the partners have got a PDUFA date of Oct. 20 which could expand the label on their interleukin-4 and -13 inhibitor to include asthma.

Exercise
Looking to expand Dupixent • Source: Shutterstock

Sanofi and Regeneron Pharmaceuticals Inc.'s hopes to turn their eczema drug Dupixent (dupilumab) from a big-seller into a mega-blockbuster have been raised by the news that the FDA is reviewing the therapy as a treatment for asthma.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Respiratory

PureTech Weighs Up Pros And Cons Of Going Private

 
• By Kevin Grogan

The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.

Paratek To Acquire Optinose, Expanding Portfolio Beyond Antibiotics

 
• By Joseph Haas

Paratek agrees to acquire Optinose in a “take-private” deal valued at $330m, adding chronic rhinosinusitis product Xhance to its antibiotic Nuzyra.

Trevi Gets A Clap On The Back For Chronic Cough Data

 
• By Jessica Merrill

A Phase IIa trial studying Haduvio for the treatment of refractory chronic cough showed a benefit for patients, opening the door to a broad market and impressing investors.

AstraZeneca And GSK Put Spotlight On Nasal Polyps Space

 
• By Kevin Grogan

Complete datasets on Tezspire and depemokimab caught the eye at the AAAAI/WAO meeting in San Diego and while the AstraZeneca/Amgen drug appears to be more efficacious, the GSK candidate offers greater convenience.

More from Therapy Areas

In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II

 
• By Sushmita Panda

BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.

Telix Moves TLX101 Forward On Encouraging Early Brain Cancer Data

 
• By Alaric DeArment

The company is planning to start a registrational program on its home turf in Australia and is planning to bring the therapy to the US as well.

Leqembi Launch Set For Germany And Austria As EU Approval Finally Comes

 
• By Neena Brizmohun

Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.